Skip to main content
SpringerLink
Log in

Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997–2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR)

  • Chapter
  • First Online:
Cancer Drug Safety and Public Health Policy

Part of the book series: Cancer Treatment and Research ((CTAR,volume 184))

  • 272 Accesses

Abstract

Adverse drug/device reactions (ADRs) serious enough to lead to box warnings on drug labels or drug withdrawals occur in about one fifth of all new molecular entities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moore TJ, Cohen MR, Furberg CD (2007) Serious adverse drug events reported to the food and drug administration, 1998–2005. Arch Intern Med 167:1752–1759

    Article  PubMed  Google Scholar 

  2. Bennett CL, Schooley B, Taylor M et al (2019) Caveat Medicus: clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS ONE 14 Article e0219521

    Google Scholar 

  3. Rossiter W (2011) A first book of algebra, including the binomial theorem. Nabu Press, Charleston, SC

    Google Scholar 

  4. Pfeffer MA, Burdmann EA, Chen C-Y et al (2009)A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032

    Google Scholar 

  5. Leyland-Jones B, The B.E.S.T. Investigators, Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460

    Google Scholar 

  6. Singh AK, Szczech L, Tang KL et al (2006) CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098

    Google Scholar 

  7. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080

    Article  CAS  PubMed  Google Scholar 

  8. Nussmeier NA, Whelton AA, Brown MT et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091

    Article  CAS  PubMed  Google Scholar 

  9. Connolly HM, Crary JL, McGoon MD et al (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581–588

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SONAR (Southern Network on Adverse Reactions) Program, University of South Carolina College of Pharmacy, Columbia, SC, 29208, USA

    Courtney R. Lubaczewski, Nancy F. Olivieri, William R. Hrushesky & Charles L. Bennett

Authors
  1. Courtney R. Lubaczewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy F. Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William R. Hrushesky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles L. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles L. Bennett .

Editor information

Editors and Affiliations

  1. College of Pharmacy, University of South Carolina, Columbia, SC, USA

    Charles Bennett

  2. College of Pharmacy, University of South Carolina, Columbia, SC, USA

    Courtney Lubaczewski

  3. College of Pharmacy, University of South Carolina, Columbia, SC, USA

    Bartlett Witherspoon

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lubaczewski, C.R., Olivieri, N.F., Hrushesky, W.R., Bennett, C.L. (2022). Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997–2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR). In: Bennett, C., Lubaczewski, C., Witherspoon, B. (eds) Cancer Drug Safety and Public Health Policy. Cancer Treatment and Research, vol 184. Springer, Cham. https://doi.org/10.1007/978-3-031-04402-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-04402-1_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-04401-4

  • Online ISBN: 978-3-031-04402-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation